Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024

SAN FRANCISCO and SINGAPORE, May 13, 2024 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced two presentations at the 20th Annual PEGS Boston summit being held from May 13-17, 2024. Data from the first presentation demonstrates the ability to direct antibodies and antibody-drug conjugates (ADCs) to rationally selected epitopes of interest on challenging disease-associated proteins. Data from the second presentation show how a novel dual-payload ADC approach has the potential to address resistance and improve the therapeutic window of ADCs.

“The data presented at PEGS show for the first time how our proprietary fourth generation antibody-drug conjugate (ADC) platform leverages novel linker and dual-payload technologies to overcome the resistance observed with earlier generation single payload ADCs. Our ADC technology has the potential to treat a large number of patients that have either intrinsic or acquired resistance to currently approved ADCs,” said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience. “We will also showcase how our proprietary Rational Antibody Discovery platform engineers immune responses in transgenic mice models so that resulting ADCs and antibodies bind to the key epitopes on disease-associated proteins for optimal drug properties. These data continue to support our belief that our next-generation ADC platform can generate best-in-class ADCs that address payload resistance, optimize tumor specificity, and enhance payload delivery, and therefore maximize the anti-tumor potential of ADCs.”

Presentation details:

Title: Engineering Immune Responses for Epitope-Focused Antibody Discovery
Presenter: Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer
Session: Display of Biologics - Novel Platforms
Date/Time: Monday, May 13, 2024, 1:45 p.m. ET

Title: Overcoming Payload Resistance with Dual-Payload ADCs
Presenter: Ben Ayers, DPhil, Vice President, Antibody-Drug Conjugates
Session: Driving Clinical Success in Antibody Drug Conjugates - Novel payloads and MOAs
Date/Time: Friday, May 17, 2024, 9:30 a.m. ET

About Hummingbird Bioscience’s ADC Platform

The 4th generation ADC platform developed by Hummingbird Bioscience aims to address the key limitations in efficacy and safety of current approved ADCs. The ADC platform combines the company’s AI-enabled Rational Antibody Discovery Platform and proprietary linker and dual-payload technologies to unlock the power of dual-payload approaches against the most important disease-associated proteins. The platform engineers potentially best-in-class ADCs that address payload resistance, optimize payload delivery and tumor specificity, and maximize anti-tumor cytotoxic potential.

About Hummingbird Bioscience’s Rational Antibody Discovery Platform

The Rational Antibody Discovery (RAD) platform is designed to address the challenges of traditional antibody approaches. This technology enables the company to identify critical functional regions of a target protein using mAbPredict, a machine learning-enabled technology platform that identifies optimal regions to target, and then drives production of antibodies against these epitopes using mAbHits, a proprietary immuno-engineering technology that directs the antibody response to pre-determined epitopes of interest in the proprietary transgenic HMBD Abvantage mouse. Unlike classical approaches to antibody discovery that have limited control over antibody binding regions, and hence, ability to target optimal epitopes, mAbHits ensures in vivo generation and affinity maturation of antibodies against only the optimal epitope. This systematic and rational approach to antibody discovery opens up the potential of discovering antibodies to specific regions of many important “hard targets” that have not been drugged or are inadequately drugged to date. The RAD platform has produced multiple antibodies and ADCs that effectively target disease-associated proteins, including two antibodies that are currently in Phase I trials (HMBD-001 and HMBD-002) and a recently out-licensed ADC (HMBD-501) that will enter the clinic in 2024.

About Hummingbird Bioscience

Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. To address key challenges with current antibody-drug conjugate (ADC) therapies, Hummingbird Bioscience is building a pipeline of next-generation ADCs using its proprietary antibody discovery and linker/payload platforms. The company has a pipeline of ADCs in preclinical development and other novel biologics including monoclonal antibodies, HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I and a recently out-licensed ADC (HMBD-501) that will enter the clinic this year. The Hummingbird Bioscience approach combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.

For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.

Contacts:

Media
Crystal Ho
c.ho@hummingbirdbio.com
media@hummingbirdbio.com
+65 6979 5580

Investors
investors@hummingbirdbio.com


Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024

THỦ THUẬT HAY

Cách soạn thảo bằng giọng nói với ứng dụng Speechnotes

Với ứng dụng Speechnotes – Speech To Text, bạn có thể soạn thảo như một phần mềm soạn thảo văn bản thông thường hoặc đặc biệt hơn là nhập văn bản bằng giọng nói với hơn 100 ngôn ngữ, trong đó có tiếng Việt.

Chuyển ảnh nhanh giữa iPhone với các thiết bị khác không cần cắm dây

Bạn có bao giờ cảm thấy phiền phức khi mỗi lần cần chuyển ảnh từ iPhone sang máy tính hay từ iPhone sang một iPhone khác không?...

12 bước để pivot startup

Nếu nhiều startup thực hiện pivot thì có lẽ đã có nhiều startup tồn tại hơn. Pivot là một bí mật để tồn tại. Học cách pivot sẽ giúp bạn cứu startup của mình khỏi thất bại và tiếp tục phát triển trong thời gian dài.

Hướng dẫn cách giảm dung lượng PDF Online không mất tiền

File PDF dung lượng lớn ảnh hưởng khá nhiều đến quá trình chia sẻ. Tuy nhiên, nếu biết cách giảm dung lượng PDF Online thì việc chia sẻ file cho mọi người sẽ trở nên dễ dàng hơn rất nhiều. Trong bài viết này Viettel

Hướng dẫn xem mật khẩu đã lưu trên Chrome cho Android

Cuối cùng người dùng Android cũng được bổ sung tính năng xem mật khẩu đã lưu, vốn quá quen thuộc trên Chrome máy tính. Chỉ cần cập nhật lên Chrome 62 bạn sẽ xem được mọi mật khẩu đã lưu ngay trong ứng dụng, thay vì

ĐÁNH GIÁ NHANH

Đánh giá Redmi Note 4: Một thiết bị đậm chất Xiaomi

Sau khi Xiaomi chính thức bước chân vào Việt Nam, chiếc Redmi Note 4 đang là chiếc smartphone được nhiều người chú ý ở phân khúc dưới 5 triệu. Mời...

Đập hộp smartband Samsung Gear Fit2 Pro giá 4,2 triệu đồng

Samsung Gear Fit2 Pro là bản nâng cấp của Samsung Gear Fit2 ra mắt hồi năm ngoái với điểm nhấn ở chuẩn kháng nước 'khủng' 5 ATM.

Đánh giá chi tiết Vibe X3: Với 5 triệu, chúng ta được gì ?

Xuất hiện không cần quá ồn ào, nhưng Lenovo Vibe X3 thực sự đang là một cơn sốt trong cộng đồng yêu công nghệ những ngày gần đây. Nào, hãy cùng...